Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
exarafenib (KIN-2787) / Pierre Fabre
KN-8701, NCT04913285: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors	Recruiting	1	400	Europe, US, RoW	KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib	Pierre Fabre Medicament	Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma	11/28	03/29
KIN-3248 / Xoma
NCT05242822: A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations	Terminated	1	54	Europe, US, RoW	KIN-3248	Kinnate Biopharma	Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma	10/24	10/24
KIN004 / Xoma
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
exarafenib (KIN-2787) / Pierre Fabre
KN-8701, NCT04913285: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors	Recruiting	1	400	Europe, US, RoW	KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib	Pierre Fabre Medicament	Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma	11/28	03/29
KIN-3248 / Xoma
NCT05242822: A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations	Terminated	1	54	Europe, US, RoW	KIN-3248	Kinnate Biopharma	Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma	10/24	10/24
KIN004 / Xoma
No trials found